menu
    • menu

    Company profile for ReViral

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an...
    ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an adult stem-cell transplant patient population. In addition, the company has an N-protein inhibitor program in late preclinical development. Both programs were discovered in-house.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ReViralunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage Hertfordshire
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://reviral.co.uk/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/reviral
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/reviral_ltd

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer snaps up rights to RSV therapy left behind in ReViral
    Pfizer snaps up rights to RSV therapy left behind in ReViral

    20 Dec 2022

    // Gabrielle Masson FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/pfizer-puts-20m-rights-lianbio-rsv-program-greater-china

    Gabrielle Masson FIERCEBIOTECH
    20 Dec 2022
    Share Share
    Pfizer Completes Acquisition Of ReViral
    Pfizer Completes Acquisition Of ReViral

    10 Jun 2022

    // CPI

    https://www.competitionpolicyinternational.com/pfizer-completes-acquisition-of-reviral/

    CPI
    10 Jun 2022
    Share Share
    Pfizer buys a private biotech and its RSV drug research
    Pfizer buys a private biotech and its RSV drug research

    08 Apr 2022

    // K. Jensen BIOPHARMADIVE

    https://www.biopharmadive.com/news/pfizer-rsv-reviral-acquisition-virus-drug/621751/

    K. Jensen BIOPHARMADIVE
    08 Apr 2022
    Share Share
    ReViral Appoints Brett Haumann as Chief Medical Officer
    ReViral Appoints Brett Haumann as Chief Medical Officer

    17 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220117005047/en

    BUSINESSWIRE
    17 Jan 2022
    Share Share
    ReViral to continue Phase II paediatric trial of sisunatovir for RSV
    ReViral to continue Phase II paediatric trial of sisunatovir for RSV

    17 Jun 2021

    // CLINICAL TRAILS ARENA

    https://www.clinicaltrialsarena.com/news/reviral-paediatric-trial-sisunatovir/

    CLINICAL TRAILS ARENA
    17 Jun 2021
    Share Share
    ReViral Announces Positive Recommendation by the DSMC for Sisunatovir
    ReViral Announces Positive Recommendation by the DSMC for Sisunatovir

    16 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210616005103/en/ReViral-Announces-Positive-Recommendation-by-the-Data-Safety-Monitoring-Committee-to-Continue-the-Phase-2-Clinical-Study-of-Sisunatovir-for-Treatment-of-Respiratory-Syncytial-Virus-Infections-in-Hospitalized-Infants

    BUSINESSWIRE
    16 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search